Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

NCT05851014 is registered in ClinicalTrials.gov with Genor Biopharma Co., Ltd. as lead sponsor.

NCT NCT05851014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05851014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting
Lead sponsor
Genor Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
January 14, 2022
Completion date
January 30, 2027
Enrollment
350 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer